Evidence map›Paper›PMID 40660139›Full record

ArticleBMC medicine2025

Mpox stigma in the UK and implications for future outbreak control: a cross-sectional mixed methods study.

Amy Paterson, Ashleigh Cheyne, Harun Tulunay, Chloe Orkin, Will Nutland, Jake Dunning, Jeni Stolow, Nina Gobat, Piero Olliaro, Amanda Rojek and 1 more

Abstract read
In one paragraph

Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Amy PatersonPandemic Sciences Institute, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7DQ, UK. amy.paterson@ndm.ox.ac.uk.
Ashleigh CheynePandemic Sciences Institute, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7DQ, UK.
Harun TulunayPositively UK, 14 St. Marys House, Chillingworth Road, London, N7 8SH, UK.
Chloe OrkinCentre for Immunobiology, SHARE Collaborative, Blizard Institute, Queen Mary University of London, London, UK.
Will NutlandThe Love Tank, The Green House, 244-254 Cambridge Heath Road, London, E2 9DA, UK.
Jake DunningPandemic Sciences Institute, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7DQ, UK.
Jeni StolowTulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA.
Nina GobatNuffield Department of Primary Care Health Services, University of Oxford, 32 Woodstock Road, Oxford, OX2 6HT, UK.
Piero OlliaroPandemic Sciences Institute, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7DQ, UK.
Amanda RojekPandemic Sciences Institute, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7DQ, UK.
Outbreak Stigma Assessment Expert Group

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundStigma emerged as a prominent public health challenge in the global mpox outbreak that began in 2022, impeding outbreak control efforts and the well-being of affected individuals. Addressing stigma is important for improving infection prevention and control. Despite frequent mention in public and policy discourse, robust assessment of mpox stigma is lacking. This study investigated the causes, manifestations, and impacts of mpox-related stigma in the UK, focusing on anticipated stigma among directly and indirectly affected communities.

methodsWe conducted an online, mixed-methods cross-sectional survey to assess mpox stigma. We developed and content validated a new tool, the Stigma Survey and Community-based Assessment for New and Re-emerging outbreaks (Stigma-SCANR) for this purpose. Through quota sampling, the survey targeted populations most affected by mpox at the time of data collection (March-July 2024), including gay, bisexual, and other men who have sex with men (GBMSM), and healthcare workers. The survey primarily explored anticipated stigma. Respondents with previous mpox diagnoses were asked about personal experiences of stigma.

resultsOf 479 respondents who initiated the survey, 437 (91%) were included in analyses. In modules related to drivers of stigma, pre-existing prejudices towards associated groups such as GBMSM and migrants were emphasised, alongside fear and misinformation. On average, respondents anticipated higher levels of negative judgement and unwarranted avoidance compared to other forms of social stigma, particularly from casual partners and the public. Among the 13 respondents who reported a previous mpox diagnosis, 11 (85%) had experienced mpox-related stigma. Nearly a quarter of respondents (24%) said they would not, or were unlikely to, tell a recent sexual partner about an mpox diagnosis. Feelings of shame were considered the most common barrier to care-seeking (299 respondents, 68%).

conclusionsThis analysis of mpox stigma in the UK offers insights for international outbreak response, particularly in countries with similarly affected communities. Lessons learnt may also be transferable to other disease outbreaks. We propose practical recommendations for reducing stigma in future outbreaks, including peer support initiatives, distributing accessible information about safe timelines for returning to socialising and work or school, and co-designing public communications and contact tracing programmes with affected community members.

Indexed as

Disease OutbreaksMpox, MonkeypoxSocial StigmaAdolescentAdultCross-Sectional StudiesFemaleHumansMaleMiddle AgedSexual and Gender MinoritiesSurveys and QuestionnairesUnited KingdomYoung AdultDiscriminationEmerging infectious disease outbreakHealth policyMpoxPrejudicePublic healthStigma

Identifiers

PMID40660139
PMCPMC12261657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.